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Abstract
Background: Most structured clinical data, such as diagnosis codes, are not sufficient to obtain precise phenotypes
and assess disease burden. Text mining of clinical notes could provide a basis for detailed profiles of phenotypic
traits. The objective of the current study was to determine whether drug dose, regardless of polypharmacy, is
associated with the length of clinical notes, and to determine the frequency of adverse events per word in clinical
notes.
Methods: In this observational study, we utilized restricted-access data from an electronic patient record system.
Using three methods (defined daily dose, olanzapine equivalents, and chlorpromazine equivalents) we calculated
antipsychotic dose equivalents and compared these with the number of words recorded per treatment day. For
each normalization method, the frequencies of adverse events per word in manually curated samples were
compared to dose intervals.
Results: The length of clinical notes per treatment day was positively associated with the prescribed dose for all
normalization methods. The number of adverse events per word was stable over the analyzed dose spectrum.
Conclusions: Assuming that drug dose increases with the severity of disease, the length of clinical notes can serve
as a proxy for disease severity. Due to the near-linear relationship, correction of daily word count is unnecessary
when text mining for potential adverse drug reactions.
Keywords: Adverse event, Text mining, Natural language processing, Antipsychotic drugs
Background
Currently, drug safety surveillance efforts rely heavily on
spontaneous reporting systems for post-approval moni-
toring [1]. However, such spontaneous reports suffer
from a variety of issues, including massive under-
reporting [2], and therefore alternative real-world data
approaches are being developed. One of these ap-
proaches is to monitor adverse events extracted from
clinical narratives by text mining [3] and we have
previously created a text-mining pipeline for this specific
purpose [4, 5]. In order to develop efficient text mining
approaches to investigate adverse events, a range of ob-
stacles needs to be addressed and causes of systemic
biases identified.
Safety monitoring is further complicated by polyphar-
macy and the fact that drugs may be used in higher
doses than recommended in guidelines [6], both of
which are associated with adverse drug reactions as well
as disease severity [7, 8]. Antipsychotics are a drug class
associated with frequent polypharmacy in the treatment
of seriously ill psychiatric patients [9, 10]. However,
uncovering any association between a specific
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characteristic and antipsychotic dose load is complicated
by the difficulty of comparing drugs within the drug
class. To facilitate comparisons between different anti-
psychotics, several methods for calculating antipsychotic
equivalents have been suggested [11–13] and it has been
argued that none of the methods is superior or should
be considered the gold standard [14]. By converting all
antipsychotic drugs to equivalents, polypharmacy can be
converted to one single equivalent dose and enable
comparisons.
Electronic patient records have emerged as a powerful
documentation and communication resource in health-
care systems. These records have been shown to reflect
processes and structures within healthcare systems, and
this might be important to consider when using clinical
data for research purposes [15]. Such processes could
potentially introduce study biases, or it could be that
structural components of the record could be used as
proxies for specific clinical variables, for instance disease
severity or mortality.
The current study sought to explore whether the drug
dose load is associated with the length of the clinical
notes. The analysis was performed on three subsets: All
notes recorded on the patient, notes recorded by physi-
cians, and notes recorded by nursing staff. Further, we
aimed to investigate whether the frequency of potential
adverse events per word was influenced by drug dose
load. Such associations might influence text-mining ef-
forts through systemic biases, and might therefore re-
quire some form of normalization based on the dose
each patient receives, or alternatively the number of
words in the record.
Methods
Study population
This study is based on clinical narratives and structured
prescription data from patients admitted to a Danish ter-
tiary mental health center in the period January 2000 to
June 2010. All patients treated with a minimum of one
antipsychotic drug fulfilled the inclusion criteria. We re-
quired the antipsychotic dosing data to be comprehen-
sive. This meant that we excluded all patients where the
prescription data could not be unambiguously ascer-
tained. Furthermore, we excluded patients from each
subanalysis if we could not calculate an equivalent for
one or more treatment days.
Patient characteristics
We determined the distribution of sex, mean age and
the number of diagnoses in each of the groups created
based on the three normalization methods. All diagnoses
had been assigned the appropriate International Classifi-
cation of Diseases version 10 codes [16] (ICD-10) by the
hospital.
Antipsychotic equivalents
The patients received a wide range of antipsychotic
drugs, both as monotherapy and as polypharmacy. To
enable comparison of daily drug exposures we used
three methods: defined daily dose (DDD), [11] chlorpro-
mazine equivalents [12], and olanzapine equivalents [13].
The total daily antipsychotic equivalent for each patient
and day were summed.
Clinical narratives and dose
In the study we used the daily word count to represent
the length of the clinical notes. The notes were extracted
from the medical narratives section of the electronic pa-
tient records. We used the Unix command wc to count
words. The total word count for each treatment day was
summed to form these daily word counts. We created
three groups of notes to compare whether the recording
authors’ profession had an influence: Firstly, one
category containing all clinical notes regardless of the
authors’ profession. Secondly, notes recorded by physi-
cians. Thirdly, notes recorded by nursing staff.
All daily equivalent doses were binned into dose inter-
val groups. The intervals were defined as starting from 0
and binning DDDs in intervals of 0.5 DDD, chlorpro-
mazine equivalents in intervals of 100mg, and olanza-
pine equivalents in intervals of 5 mg. The lower
boundary of each interval was greater than the cut-off
value and the upper boundary was equal to the cut-off
value (Fig. 1).
For each treatment day considered, a patient contrib-
uted with a daily equivalent dose and a medical record
word count based on all notes recorded on that day. We
calculated the average word count per day for each pa-
tient by averaging the word count per treatment day, for
all days on which the patient’s daily equivalent dose was
within the interval of each bin. To explore the associ-
ation between antipsychotic dose load and number of
words per day, the median for each bin was compared,
and the distribution of each interval for all three
methods of dose normalization was plotted. Intervals
containing less than 100 patients were excluded from
the analysis.
Influence of drug dose on the potential adverse events
per word
To investigate whether the number of potential adverse
events per clinical word was associated with the total
normalized dose, three equally wide dose intervals for
each normalization method were defined. The three in-
tervals for each normalization method were chosen to
include the broadest spectrum of doses, based on the
previously described binned dose intervals containing
ten or more patients, and the groups therefore spanned
a range of bins (Fig. 1). We manually curated all records
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Fig. 1 Initially dose interval groups were formed by binning equivalent doses. The three equivalents consisted of separate dosage intervals, all
starting from 0. DDDs were binned in intervals of 0.5 DDD, chlorpromazine equivalents were binned in intervals of 100 mg, and olanzapine
equivalents were binned in intervals of 5 mg. The length of the clinical notes was analyzed in each binned dosage interval. Three equally wide
dose intervals (low, mid, high) were defined to investigate whether the number of potential adverse events per clinical word was associated with
the total normalized dose. Intervals containing less than 10 patients were excluded from all analyses, intervals containing less than 100 patients
were only excluded from the analysis comparing the drug dose with the length of clinical notes
Table 1 Drugs covered by the conversion methods
Drug DDD Olanzapine equivalents Chlorpromazine equivalents
amisulpride YES YES NO
aripiprazole YES YES YES
chlorprothixene YES YES NO
clozapine YES YES YES
flupentixol YES YES NO
haloperidol YES YES YES
levomepromazine YES YES NO
melperone YES NO NO
olanzapine YES YES YES
paliperidone YES YES NO
penfluridol YES NO NO
perphenazine YES YES YES
pimozide YES YES NO
prochlorperazine YES YES NO
quetiapine YES YES YES
risperidone YES YES YES
sertindole YES YES NO
sulpiride YES YES NO
thioridazine YES YES YES
ziprasidone YES YES YES
zuclopenthixol YES YES NO
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from 125 randomly selected treatment days in each of
the dose intervals, multiple records were allowed to ori-
ginate from the same patient. All potential adverse
events were compared to the total amount of words re-
corded in the clinical narratives.
Results
In total 2838 patients fulfilled the inclusion criteria. Of
these 1249 patients were excluded, meaning 1589 pa-
tients were included in the analyses. Only the DDD
normalization method [11] held conversions for all anti-
psychotic drugs in all the formulations received by our
study population. The olanzapine equivalent method
[13] includes 19 out of 21 drugs and the chlorpromazine
equivalent method [12] includes 9 out of 21 drugs
(Table 1). Since we required certainty in dose calcula-
tions, there are fewer patients in the analyses using the
olanzapine and chlorpromazine normalization methods;
patient characteristics also differ (Table 2). The most
common diagnosis across normalization methods was
schizophrenia.
In total 4,903,669 notes were stored in the patient re-
cords; of these, physicians had recorded 885,964 (18%)
notes and nursing staff had recorded 3,726,529 (76%)
notes. We found a positive association between the
number of clinical note words per day and prescribed
dose for all normalization methods, irrespective of the
staff category recording the note (Fig. 2).
Three intervals were chosen to determine potential ad-
verse events per treatment day and the numbers of po-
tential adverse events per word were plotted for the
three normalization methods. The number of patients
included in the intervals spanned between 25 and 119.
(Fig. 3). The average potential adverse events per word
were determined to 0.0078 (DDD), 0.0086 (chlorpromaz-
ine equivalents), and 0.0096 (olanzapine equivalents).
Discussion
Adverse drug reactions are highly underreported and
searching for adverse events mentioned in patient re-
cords might increase our chance of discovering adverse
drug reactions experienced by patients. When extracting
adverse events, it is important to limit systemic biases.
Table 2 Patient characteristics for the cohorts covered by the three normalization methods. Diagnoses are coded in International
Classification of Diseases version 10






Number of patients 1589 1539 438
Male sex 1043
(65.6)
1010 (65.6) 287 (65.5)
Mean age in years (SD) 40.3 (6.3) 40.1 (6.4) 40.1 (6.3)
Diagnoses
F10 Alcohol related disorders 666 (41.9) 645 (41.9) 149 (34.0)
F11 Opioid related disorders 266 (16.7) 256 (16.6) 66 (15.1)
F12 Cannabis related disorders 476 (30.0) 458 (29.8) 130 (29.7)
F13 Sedative, hypnotic, or anxiolytic related disorders 255 (16.0) 247 (16.0) 57 (13.0)
F14 Cocaine related disorders 189 (11.9) 182 (11.8) 41 (9.4)
F15 Other stimulant related disorders 126 (7.9) 122 (7.9) 28 (6.4)
F19 Other psychoactive substance related disorders 225 (14.2) 218 (14.2) 60 (13.7)
F20 Schizophrenia 740 (46.6) 707 (45.9) 197 (45.0)
F21 Schizotypal disorder 105 (6.6) 103 (6.7) 28 (6.4)
F22 Delusional disorder 56 (3.5) 54 (4.9) 20 (4.6)
F23 Brief psychotic disorder 25 (1.6) 25 (1.6) 10 (2.3)
F25 Schizoaffective disorder 50 (3.1) 49 (4.9) 13 (3.0)
F31 Bipolar disorder 98 (6.2) 97 (6.3) 26 (5.9)
F32 Mayor depressive disorder, single episode 120 (7.6) 119 (7.7) 18 (4.1)
F33 Mayor depressive disorder, recurrent 197 (12.4) 193 (12.5) 40 (9.1)
F41 Other anxiety disorders 162 (10.2) 159 (10.3) 33 (7.5)
F60 Specific personality disorders 329 (20.7) 325 (21.1) 80 (18.3)
Z046 Encounter for general psychiatric examination, requested by
authority
266 (16.7) 250 (16.2) 66 (15.1)
Sørup et al. BMC Medical Research Methodology          (2020) 20:107 Page 4 of 7
In the current study we were able to identify a positive
association between the length of clinical notes and drug
load. These findings were consistent in two of the
normalization methods used, as well as across profes-
sions examined in this study. Likewise, consistently
across normalization methods, we found a near-linear
relationship between number of words in clinical notes
and potential adverse events.
We performed one analysis of dose and words with all
staff categories included. In addition, we analyzed two
subgroups (physicians and nursing staff). The remaining
staff (physical therapists, occupational therapists, psy-
chologists, social workers, secretaries) together contrib-
uted 6% of the notes. Subgroup analyses of the
remaining staff categories were not preformed due to
the small number of notes within each category. Physi-
cians and nursing staff are also the primary groups in-
volved in pharmacological treatment.
We used three different antipsychotic drug dose
normalization methods, where two methods included
only some of the antipsychotic drugs taken by our pa-
tient group, resulting in three patient cohorts. One of
these methods, normalizing by chlorpromazine equiva-
lents, had so few conversions that almost three quarters
of the original patients were excluded. This resulted in
very few patients in the designated bins, representing
mainly the very low end of daily doses expected in a
clinical setting. The results for the two other
normalization methods are consistent and span broader
daily dose ranges.
Assuming that the patients in the data set who are most
severely ill also receive higher drug doses, our results sug-
gest that length of the daily narratives could be used as a
proxy for disease severity. The number of words per day
could be used for stratifying patients, as the number of
words would serve as a predictor of disease severity. How-
ever, in the current study we have not compared disease
severity with dose and a disease severity classification
would be out of scope of the current study. We consider
alternatives such as analyses of disease severity through
diagnosis codes or number of diagnoses to be insufficient.
We deem it impossible to completely establish disease se-
verity from all ICD-10 diagnosis codes and a higher num-
ber of diagnoses does not necessarily mean a patient is
more ill. The former, is exemplified by several diseases
only having one severity level, such as “paranoid schizo-
phrenia” (ICD-10 code F20.0). The latter, could be exem-
plified by most clinicians would consider a single
schizophrenia diagnosis code to be worse than “acute
nasopharyngitis” (ICD-10 code J00.0) diagnosis code in
combination with “problems in relationship with parents
and in-laws” (ICD-10 code Z63.1).
Previous research has focused on duplication [17] or
redundancy [18] in patient records, but to our
Fig. 2 Violin plots of antipsychotic dose load and number of words
in the clinical notes per day using the three equalization methods.
The medians of the distributions are represented by black dots. The
width of each area represents a dose interval of, respectively, 0.5
DDD, 5 mg olanzapine equivalents, or 100 mg chlorpromazine
equivalents. The same intervals were used to bin data from notes
recorded by all staff categories (physicians, nursing staff, physical
therapists, occupational therapists, psychologists, social workers, and
secretaries), notes by physicians, and notes by nursing staff. The
daily note length by all staff, physicians and nursing staff are plotted
individually. Each value of the note length originates from zero and
the values are not additive. Intervals containing less than 100
patients are not plotted
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knowledge, this is the first time someone has reported a
possible association between number of words per day
and a drug treatment. The higher number of words per
treatment day could depend on various factors. We
hypothesize that patients prescribed higher doses have
more severe disease forms, receive more involuntary
treatment, are prescribed antipsychotic polypharmacy
and experience more adverse drug reactions. Any of
these would explain the need for more documentation
and thus more words in the clinical record, which also
serves as a legal document, and in some countries, for
reimbursement purposes. However, when examining the
possible association between number of words and pos-
sible adverse events in the narratives we find a linear re-
lation with a constant number of events per word. It
therefore seems like there is no need for adjustment for
the number of words in the clinical narratives when text
mining for possible adverse drug events since the results
suggest that the proportion between these two variables
is constant for all doses. Since the relationship is con-
stant we suggest that no correction factor is needed to
counteract effects from differences in note length. More
adverse events are likely experienced at higher dose
levels, as the notes recorded about patients receiving
higher doses are longer and therefore contain more po-
tential adverse events.
Since the dose analyses are performed by an algorithm
there is a risk of misclassification that would have been
identified with manual review. This risk exists in both
the dose identification as well as the adverse event iden-
tification. In addition to these limitations, it is also a
possibility that the daily dose load is not being calculated
correctly. We present findings that are consistent in the
normalization methods but still there is a risk of these
methods not producing an accurate estimate of total
daily dose. Finally, the use of data from a single center is
a limitation and the discovered potential bias might be
associated with care delivery at this specific unit.
Conclusions
The prescribed drug dose is positively associated with
the number of words recorded per day in the clinical
notes, regardless of the staff category recording the
notes. This means that the length of clinical notes in
terms of word count might serve as a proxy for disease
severity, assuming that drug dose increases along with
disease severity. The number of potential adverse events
per word in the clinical notes is close to linear and in
text mining efforts of potential adverse events per day
no correction of note length seems necessary.
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